Evotec
Logotype for Evotec SE

Evotec (EVT) investor relations material

Evotec Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Evotec SE
Q3 2026 earnings summary5 Nov, 2026

Executive summary

  • Q3 revenue was broadly stable YoY and adjusted EBITDA improved to near break-even; 9M revenue declined, while D&PD base-business net sales rose 24%.

  • FY 2026 guidance was reaffirmed, with revenue and adjusted EBITDA expected toward the upper ends of their ranges.

  • The 2030 framework targets ~€1bn revenue and an adjusted EBITDA margin above 20%.

Financial highlights

  • Q3 group revenue was €164.9m, up 0.6% YoY; at constant exchange rates it was €164.2m versus €163.9m.

  • 9M group revenue was €465.0m, down 13.1% reported and 10.8% at constant exchange rates; base revenue fell 12.4% to €441.1m.

  • Q3 adjusted group EBITDA loss narrowed to €1.6m from €15.0m; the 9M loss widened to €44.3m from €16.9m, or €39.1m at constant exchange rates.

  • 9M gross profit was €16.6m and gross margin 3.6%, versus €57.1m and 10.7% a year earlier.

  • 9M operating loss was €254.8m and net loss €195.3m; reorganization costs were €91.9m and included a €42.3m Hamburg laboratory impairment.

Outlook and guidance

  • FY 2026 guidance remains €570m–€610m revenue reported (€595m–€635m at constant FX) and an adjusted EBITDA loss of €70m–€105m (€60m–€90m at constant FX); both are expected toward the upper ends.

  • Horizon targets ~€75m annual run-rate savings by end-2027; more than 20% had been delivered by September, with 20%–30% planned for 2026.

  • The 2028 mid-range plan targets a 20% adjusted EBITDA margin; 2030 targets ~€1bn revenue and an adjusted EBITDA margin above 20%.

  • 2030 revenue mix targets are 40% D&PD base business, 20% strategic partnerships and 40% JEB.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Evotec earnings date

Logotype for Evotec SE
Q4 202616 Apr, 2027
Evotec
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Evotec earnings date

Logotype for Evotec SE
Q4 202616 Apr, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Evotec SE is a biotechnology company specializing in drug discovery and development services. The company collaborates with pharmaceutical and biotech firms, academic institutions, and research organizations to identify and develop therapeutic candidates across various disease areas, including neurology, oncology, and metabolic disorders. The company is headquartered in Hamburg, Germany, and its shares are listed on the FSE (Frankfurt Stock Exchange).